New capecitabine schedule aims to improve quality of life in colorectal cancer
NCT ID NCT07215936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial compares a new 'dose-dense' schedule of capecitabine (one week on, one week off) against the standard regimen (two weeks on, one week off) in 100 people with colorectal cancer. The main goal is to see if the new schedule improves quality of life. The study is active but no longer recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capecitabine
What this could lead to
If successful, this could offer a more convenient dosing schedule for capecitabine that maintains or improves quality of life for people with colorectal cancer.
What could go wrong
This is a small, early-phase trial with only 100 participants, so results may not apply to everyone. The new schedule may not be better than the standard one and could have different side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sohag university hospital
Sohag, Egypt